SCHEMBL163324

SCHEMBL163324

O=C(Nc1ccc(-c2cnc(C3CCN(S(=O)(=O)C(F)(F)F)CC3)s2)cc1)Nc1ccccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 7/20 0.52
TEK Q02763 3/20 0.40
CNR1 P21554 1/20 0.40
EPHB4 P54760 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
KDR P35968 2/20 0.39
KIT P10721 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
POLB P06746 2/20 0.39
LMNA P02545 1/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164736 0.91 DGAT1 (0.52) DGAT1TEKEPHB4SMN1; SMN2KDR
SCHEMBL160037 0.89 DGAT1 (0.54) DGAT1TEKCNR1SMN1; SMN2KDR
SCHEMBL163197 0.86 DGAT1 (0.52) DGAT1KDRTRPV1
SCHEMBL158428 0.84 DGAT1 (0.53) DGAT1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL28806672 0.83 KIF11 (0.41) CNR1KITTRPV1
SCHEMBL159660 0.83 DGAT1 (0.56) DGAT1TEKCNR1EPHB4SMN1; SMN2
SCHEMBL162160 0.82 DGAT1 (0.42) DGAT1CNR1KDRTRPV1
SCHEMBL162142 0.82 DGAT1 (0.56) DGAT1TEKCNR1EPHB4SMN1; SMN2
SCHEMBL162634 0.82 DGAT1 (0.56) DGAT1TEKCNR1EPHB4KDR
SCHEMBL161173 0.81 DGAT1 (0.57) DGAT1TEKCNR1EPHB4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP claimed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US claimed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO claimed
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP disclosed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US disclosed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS DGAT1, DGAT2, SOAT1 DGAT1 1/4885TEK 3387/4885CNR1 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.